Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 23, 2025Frontiers in ImmunologyOpen Access

Blinatumomab in pediatric B-acute lymphoblastic leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

YCYuan ChengZheJiang Academy of Agricultural SciencesALAiguo LiuTongji Hospital

Discussion

Loading...

Member takes

Overview

This review highlights blinatumomab's clinical efficacy and treatment-related complications in pediatric B-ALL.

Key Points

  • Blinatumomab shows substantial clinical benefits for pediatric patients with relapsed or refractory B-ALL.
  • Factors like tumor burden and T-cell function significantly influence the clinical efficacy of blinatumomab.
  • The treatment involves continuous intravenous infusion and requires careful monitoring for complications like CRS and neurotoxicity.
  • Ongoing studies aim to refine dosing strategies and improve the therapeutic precision of blinatumomab for pediatric patients.

Cite This Study

Cheng et al. (2025) studied this question.

synapsesocial.com/papers/689a061be6551bb0af8cdb66https://doi.org/10.3389/fimmu.2025.1611701
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Blinatumomab Administration in Pediatric B-Lineage ALL: Expert Recommendations From the Children’s Oncology Group2025
  2. 2Blinatumomab vs. chemotherapy in pediatrics B-cell ALL: A meta-analysis of randomized controlled trials2025
  3. 3Efficacy and safety of blinatumomab as frontline treatment for infant acute lymphoblastic leukemia2025
  4. 4Leukemia Burden Impacts the Efficacy and Toxicity of Blinatumomab in Pediatric B‐Cell Acute Lymphoblastic Leukemia2025
  5. 5Blinatumomab demonstrates MRD eradication in MRD-positive/chemotherapy-delayed pediatric B-ALL and high response in relapsed/refractory cases: a multicenter cohort study2025